'Plant derived drugs aren't uncommon or inferior.
The advantage with biosynthesis is mainly reduced time and cost.'
If one route of manufacturing produces a higher volume with less costs, how is the other method not inferior? I know it is not uncommon, but wouldn't cannabis variability make it more difficult than your average plant? The more variable the species = the more synthetics make the better route? Why are you even bothering Growing it considering the risks and GMP costs....
Targeted synthetics outperform the plant 10/10 times for that specific indication. Even if some of the 550ish compounds have a net positive effect, clearly it is not big enough to warrant smoking/edibles over a synthetic. And if they do have a benefit, that will be discovered and drugs improved one day.
Are cannabinoids via IV the best? The study I referenced would indicate not.....
'hough I'm skeptical that NB1111 will be successful because of tolerance'
Tolerance to what? The latest research said 1%< THC?
'"But if it's valued at a couple hundred million $$ then that's not bad for a few years work...".
Not bad at all, is that just a hypothetical figure or what you actually think it could be worth to Nemus? '
If the CINV market is 2b, and they can get 5% of that for a sustained period, you can do the math
News 
Market Data 
Discover 
